Incyte scores speedy FDA review for JAK cream in atopic dermatitis; Lilly backs $90M raise for Regor
Incyte’s stalwart JAK inhibitor Jakafi has raced out to blockbuster sales without the safety burden of other drugs in the class. Now, the drugmaker’s quest …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
